John A. Libertino, MD, chairman, Institute of Urology, Lahey Clinic, Burlington Mass., responds to the USTF recommendations on PSA testing

Contact: Scott Hartman
Communications & Marketing
Lahey Clinic
(781) 744-8873
Scott.V.Hartman@lahey.org

“Prostate cancer is a complicated and controversial topic, with high quality evidence available to both support and refute the benefits of screening and treatment. The most salient issue with prostate cancer is overtreatment, not PSA screening. Lahey Clinic has a robust, active surveillance program for appropriate low risk patients.

It is our opinion that eliminating PSA screening before newer screening tools become available is a disservice to patients. Staff at the Lahey Clinic Institute of Urology would be delighted to see patients who wish to discuss the pros and cons of screening.”

Other Recommendations 

While the USPTF has recommended against PSA based screening, other organizations have not followed suit:

·The American Cancer Society (ACS) recommends that men have a chance to make an informed decision with their provider and, after discussion, those who wish to be screened should be offered PSA and DRE.

·The American Urological Association (AUA) also recommends that PSA and DRE be offered for those who wish to be screened and that screening should be offered to men over age 40 with a life expectancy of >10 years.